Last reviewed · How we verify
OBV/PTV/r
OBV/PTV/r is a NS5A inhibitor/protease inhibitor combination Small molecule drug developed by AbbVie. It is currently in Phase 3 development for Chronic hepatitis C virus infection, Genotype 1, 2, 4, 5, or 6 infection. Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir (r) also known as Norvir, VIEKIRAX combination tablets.
Ombitasvir/paritaprevir/ritonavir is a combination of a protease inhibitor and a non-nucleoside NS5A inhibitor used to treat hepatitis C virus infection.
Ombitasvir/paritaprevir/ritonavir is a combination of a protease inhibitor and a non-nucleoside NS5A inhibitor used to treat hepatitis C virus infection. Used for Chronic hepatitis C virus infection, Genotype 1, 2, 4, 5, or 6 infection.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
AbbVie is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | OBV/PTV/r |
|---|---|
| Also known as | ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir (r) also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE |
| Sponsor | AbbVie |
| Drug class | NS5A inhibitor/protease inhibitor combination |
| Target | NS5A protein/NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Ombitasvir is a NS5A inhibitor that works by binding to the NS5A protein of the hepatitis C virus, preventing the virus from replicating. Paritaprevir is a protease inhibitor that works by binding to the NS3/4A protease of the hepatitis C virus, preventing the virus from replicating. Ritonavir is a protease inhibitor that is used in combination with other medications to increase their effectiveness and reduce the risk of resistance.
Approved indications
- Chronic hepatitis C virus infection
- Genotype 1, 2, 4, 5, or 6 infection
Common side effects
- Fatigue
- Nausea
- Headache
Key clinical trials
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection (PHASE2)
- Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients (PHASE1, PHASE2)
- Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 (PHASE1, PHASE2)
- Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease (PHASE4)
- Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OBV/PTV/r CI brief — competitive landscape report
- OBV/PTV/r updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about OBV/PTV/r
What is OBV/PTV/r?
How does OBV/PTV/r work?
What is OBV/PTV/r used for?
Who makes OBV/PTV/r?
Is OBV/PTV/r also known as anything else?
What drug class is OBV/PTV/r in?
What development phase is OBV/PTV/r in?
What are the side effects of OBV/PTV/r?
What does OBV/PTV/r target?
Related
- Drug class: All NS5A inhibitor/protease inhibitor combination drugs
- Target: All drugs targeting NS5A protein/NS3/4A protease
- Manufacturer: AbbVie — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Chronic hepatitis C virus infection
- Indication: Drugs for Genotype 1, 2, 4, 5, or 6 infection
- Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir (r) also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing